Actinium Pharmaceuticals named Gregory Bergonio as its director of clinical operations. The new director of clinical operations will be responsible for the company's Actimab-A phase II clinical trial programme. Bergonio moves from Novartis, where he served as an expert clinical manager in the Swiss firm's oncology global development unit, specializing in acute myeloid leukemia.